Aligos Therapeutics (ALGS) Revenue (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly Revenue came in at $2.8 million in Q1 2026, up 809.97% YoY from $311000.0 in Q1 2025, and up 1574.56% on a QoQ basis from $169000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Revenue (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of Revenue data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Revenue rose 809.97% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 8189.8% YoY) and the FY2025 annual result came in at $2.2 million, up 554.49% from the prior year.
- Revenue climbed to $2.8 million in Q1 2026, from $169000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $13.9 million in Q4 2022 to a low of -$2.7 million in Q4 2024.
- A 5-year average of $2.0 million and a median of $1.1 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue jumped 3689.37% — and 2024, when it plunged 134.71%.
- Tracing ALGS's Revenue over 5 years: stood at $13.9 million in 2022, then plunged by 108.18% to -$1.1 million in 2023, then sank by 134.71% to -$2.7 million in 2024, then jumped by 106.33% to $169000.0 in 2025, then surged by 1574.56% to $2.8 million in 2026.
- The last three Revenue figures came in at $2.8 million (Q1 2026), $169000.0 (Q4 2025), and $965000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.83 Mn |
| Dec 31, 2025 | 169,000.00 |
| Jun 30, 2025 | 965,000.00 |
| Mar 31, 2025 | 311,000.00 |
| Dec 31, 2024 | -2.67 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 694,000.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 4.29 Mn |
| Mar 31, 2023 | 140,000.00 |
| Dec 31, 2022 | 13.91 Mn |
| Sep 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 367,000.00 |
| Sep 30, 2021 | 1.54 Mn |
| Jun 30, 2021 | 1.55 Mn |
| Mar 31, 2021 | 910,000.00 |